Johnson & Johnson said the FDA approved Icotyde (icotrokinra), a once-daily oral treatment for adults with moderate to severe ...

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...

The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Picankibart is a recombinant anti-interleukin 23p19 ...

AbbVie (ABBV) stock dips as BNP warns J&J’s (JNJ) newly FDA-approved plaque psoriasis pill, Icotyde, may challenge its blockbuster drug, Skyrizi. Read more here.

Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection. Botulinum toxin A (BoNT-A) injection emerged as an effective therapy for patients ...

Please provide your email address to receive an email when new articles are posted on . A 2.5 mg/mL dose of triamcinolone acetonide showed equally as efficacious treatment for nail psoriasis vs.

The webinar will be broadcast via Zoom. Interested participants can register using the following LINK. The discussion will provide an in-depth exploration of the plaque psoriasis landscape, current ...